Expected Shortage of TB Tests Prompts New CDC Recommendations |
Clinical News
eMediNexus Coverage from: 
Expected Shortage of TB Tests Prompts New CDC Recommendations

3 Read Comments                

The Centers for Disease Control and Prevention (CDC) has issued new recommendations for tuberculosis (TB) skin testing in response to the anticipated 3- to 10-month nationwide shortage of Aplisol (Par Pharmaceuticals), a purified-protein derivative (PPD) tuberculin antigen approved by the US Food and Drug Administration (FDA) for tuberculin skin tests (TSTs).

The report was published this week in MMWR. The CDCs recommendations are intended to address the potential decrease in TB testing because of the shortage.

To comment on this article,
create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies
Create Account

Already registered?

Login Now